RUNX1T1 and acute myeloid leukemia: Patients with prognostically favorable genetic subtypes (CBFB::MYH11, RUNX1::RUNX1T1, CEBPAm and NPM1m) were treated predominantly on the SR arm of the AML-BFM 2012 Registry protocol.